With evening/morning split dosing, NER1006 was as effective as trisulfate for overall bowel and right-sided colon cleansing. Adverse event rates were slightly higher with NER1006 than trisulfate, but did not compromise tolerability, adherence, or efficacy. (Clinical trial registration number: NCT02254486.).

No abstract

This randomized, placebo-controlled trial found that Creon 10 treatment controlled steatorrhea, as reflected in reduced fat excretion, decreased stool frequency and improved stool consistency. Creon 10 treatment was safe and well tolerated.

No abstract

NOTE. The primary investigators listed are those who enrolled at least 1 patient. NC, not contactable.

Introduction: The risk of colorectal cancer (CRC) in patients with cystic fibrosis (PWCF) is 10times greater than the general population and 30times greater posttransplant. Given the increased prevalence of adenomatous colonic polyps at a younger age as well as increasing evidence of CFTR mutations as a contributing genetic risk factor cystic fibrosis (CF) should be considered a genetic adenomatous polyposis and colon cancer syndrome. Due to this increased risk new screening guidelines were published in Gastroenterology by the CF Colorectal Cancer Screening Task Force in 2018. Aims: To benchmark current practise at our centre against current guidelines for colonoscopy screening in PWCF Methods: Our endoscopy database was interrogated from 2012 to present to identify PWCF who received a previous colonoscopy. Data including basic demographics, age at index colonoscopy, findings at colonoscopy and scheduling of follow-up colonoscopies was collected. Results: Group 1: PWCF non-transplant cohort; 161 patients were included. 26 were >40years. 4 (15.38%) patients had a previous colonoscopy (total number colonoscopies Z 4). No colonoscopies were done for screening, all were done as patients were symptomatic. One patient had a polyp at colonoscopy. Adenoma detection rate (ADR) was 25%. 22 (84.62%) patients >40 have no previous colonoscopy. Surveillance for CRC in this cohort has yet to be implemented with 0% compliance with present guidelines to date. Group 2: PWCF post solid-organ transplant; 16 patients were included. 13 were >30 years. 11 (84.62%) patients had a previous colonoscopy (total number colonoscopies Z 20). (Graph 2). Reasons for index colonoscopy: 5 screening, 3 symptomatic, 3 no indication on report. 45.45% of index colonoscopies were done for screening. 3 patients had polyps found at index colonoscopy (2 adenomas high grade dysplasia, 4 adenomas low grade dysplasia) and surveillance colonoscopies were arranged subsequently for all these patients. ADR was 27.27%. Current practise in the post transplant cohort is close to new recommendations with 84% compliance however only 45.45% of index colonoscopies were done initially for screening. Conclusion: Current guidelines are only in existence just over 12months. Our analysis suggests there is an awareness of the need for CRC screening in the post-transplant cohort with screening actively being performed in our centre in this cohort. However there is still need for improvement in this group. In PWCF with no previous transplant screening has not been a priority and needs to be implemented. Compliance in our centre with screening guidelines is sub-par. Currently we are implementing a screening programme in keeping with current guidelines to improve compliance with screening in PWCF at our centre.

No abstract

No abstract